Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?

J. Burisch , H. Vardi , D. Schwartz , Z. Krznaric (1) , P. L. Lakatos (2) , Mathurin Fumery (3, 4) , L. Kupcinskas , F. Magro (5) , E. Belousova , P. Oksanen , N. Arebi , E. Langholz , S. Turcan , R. d'Inca , V. Hernandez , D. Valpiani , Z. Vegh , M. Giannotta , K. H. Katsanos , D. Duricova , K. R. Nielsen , H. A. L. Kievit , P. Ellul (6) , R. Salupere , A. Goldis , I. Kaimakliotis , N. Pedersen , V. Andersen (7) , J. Halfvarson , S. Sebastian (8) , J. F. Dahlerup , P. Munkholm , S. Odes

1 Zagreb University Hospital
2 Semmelweis University [Budapest]
3 CHU Amiens-Picardie
4 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1
5 Hospital de São João [Porto]
6 CGIAR - Consultative Group on International Agricultural Research [CGIAR]
7 Regional Hospital of Viborg, Medical Department, Viborg, Denmark
8 Castle Hill Hospital, Hull & East Yorkshire Hospitals NHS Trust

Domaines: Sciences du Vivant [q-bio]

J. Burisch, H. Vardi, D. Schwartz, Z. Krznaric, P. L. Lakatos, et al.. Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?. Journal of Crohn's and Colitis, 2019, 13 (1), pp.S9-S10. ⟨10.1093/ecco-jcc/jjy222.014⟩. ⟨hal-03552297⟩